MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 318889 | Name: Tolterodine
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Tolterodine is an antimuscarinic drug that is used for symptomatic treatment of urinary incontinence.

Chemical Structure

Tolterodine
CAS#124937-51-5 (free base)

Theoretical Analysis

MedKoo Cat#: 318889

Name: Tolterodine

CAS#: 124937-51-5 (free base)

Chemical Formula: C22H31NO

Exact Mass: 325.2406

Molecular Weight: 325.49

Elemental Analysis: C, 81.18; H, 9.60; N, 4.30; O, 4.92

Price and Availability

Size Price Availability Quantity
5mg USD 250.00
10mg USD 450.00
25mg USD 950.00
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
124937-51-5 (free base) 124937-52-6 (tartrate)
Synonym
Tolterodine, Detrol, Detrusitol, PHA-686464B
IUPAC/Chemical Name
2-[(1R)-3-[di(propan-2-yl)amino]-1-phenylpropyl]-4-methylphenol
InChi Key
OOGJQPCLVADCPB-HXUWFJFHSA-N
InChi Code
InChI=1S/C22H31NO/c1-16(2)23(17(3)4)14-13-20(19-9-7-6-8-10-19)21-15-18(5)11-12-22(21)24/h6-12,15-17,20,24H,13-14H2,1-5H3/t20-/m1/s1
SMILES Code
OC1=CC=C(C)C=C1[C@@H](C2=CC=CC=C2)CCN(C(C)C)C(C)C
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 325.49 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Gacci M, Sebastianelli A, Salvi M, Schiavina R, Brunocilla E, Novara G, De Nunzio C, Tubaro A, Oelke M, Gravas S, Carini M, Serni S. Tolterodine in the Treatment of Male LUTS. Curr Urol Rep. 2015 Sep;16(9):60. doi: 10.1007/s11934-015-0531-9. Review. PubMed PMID: 26149965. 2: Gacci M, Novara G, De Nunzio C, Tubaro A, Schiavina R, Brunocilla E, Sebastianelli A, Salvi M, Oelke M, Gravas S, Carini M, Serni S. Tolterodine extended release in the treatment of male OAB/storage LUTS: a systematic review. BMC Urol. 2014 Oct 27;14:84. doi: 10.1186/1471-2490-14-84. Review. PubMed PMID: 25348235; PubMed Central PMCID: PMC4230346. 3: Angulo JC, Valpas A, Rejas J, Linden K, Kvasz M, Snedecor SJ. Cost effectiveness of fesoterodine and tolterodine for the treatment of overactive bladder with urge urinary incontinence in Spain and Finland. Clin Drug Investig. 2014 May;34(5):297-307. doi: 10.1007/s40261-014-0178-1. Review. PubMed PMID: 24567280. 4: Medhi B, Mittal N, Bansal D, Prakash A, Sarangi SC, Nirthi B. Comparison of tolterodine with standard treatment in pediatric patients with non-neurogenic dysfunctional voiding/over active bladder: a systematic review. Indian J Physiol Pharmacol. 2013 Oct-Dec;57(4):343-53. Review. PubMed PMID: 24968572. 5: Elterman DS, Chughtai B, Kaplan SA, Barkin J. Tolterodine for the treatment of urge urinary incontinence. Expert Opin Pharmacother. 2013 Oct;14(14):1987-91. doi: 10.1517/14656566.2013.823158. Epub 2013 Jul 26. Review. PubMed PMID: 23885788. 6: Omotosho T, Chen CC. Update on tolterodine extended-release for treatment of overactive bladder. Open Access J Urol. 2010 Nov 23;2:185-91. doi: 10.2147/OAJU.S7232. Review. PubMed PMID: 24198627; PubMed Central PMCID: PMC3818890. 7: Chung DE, Te AE. Tolterodine extended-release for overactive bladder. Expert Opin Pharmacother. 2009 Sep;10(13):2181-94. doi: 10.1517/14656560903167965. Review. PubMed PMID: 19663610. 8: Malhotra B, Gandelman K, Sachse R, Wood N, Michel MC. The design and development of fesoterodine as a prodrug of 5-hydroxymethyl tolterodine (5-HMT), the active metabolite of tolterodine. Curr Med Chem. 2009;16(33):4481-9. Review. PubMed PMID: 19835561. 9: Ulahannan D, Wagg A. The safety and efficacy of tolterodine extended release in the treatment of overactive bladder in the elderly. Clin Interv Aging. 2009;4:191-6. Epub 2009 May 14. Review. PubMed PMID: 19503781; PubMed Central PMCID: PMC2685240. 10: Bolge SC, McDonnell DD, Chen A, Wan GJ. Patient satisfaction with extended release tolterodine or oxybutynin in overactive bladder. Curr Med Res Opin. 2007 Aug;23(8):1903-12. Review. PubMed PMID: 17610806. 11: Rovner ES. Tolterodine for the treatment of overactive bladder: a review. Expert Opin Pharmacother. 2005 Apr;6(4):653-66. Review. PubMed PMID: 15934891. 12: Garely AD, Burrows L. Benefit-risk assessment of tolterodine in the treatment of overactive bladder in adults. Drug Saf. 2004;27(13):1043-57. Review. PubMed PMID: 15471509. 13: Wefer J, Truss MC, Jonas U. Tolterodine: an overview. World J Urol. 2001 Nov;19(5):312-8. Review. PubMed PMID: 11760779. 14: Crandall C. Tolterodine: a clinical review. J Womens Health Gend Based Med. 2001 Oct;10(8):735-43. Review. PubMed PMID: 11703885. 15: Clemett D, Jarvis B. Tolterodine: a review of its use in the treatment of overactive bladder. Drugs Aging. 2001;18(4):277-304. Review. PubMed PMID: 11341475. 16: Guay DR. Tolterodine, a new antimuscarinic drug for treatment of bladder overactivity. Pharmacotherapy. 1999 Mar;19(3):267-80. Review. PubMed PMID: 10221366. 17: Hills CJ, Winter SA, Balfour JA. Tolterodine. Drugs. 1998 Jun;55(6):813-20; discussion 821-2. Review. PubMed PMID: 9617596. 18: Salvatore S, Serati M, Bolis P. Tolterodine for the treatment of overactive bladder. Expert Opin Pharmacother. 2008 May;9(7):1249-55. doi: 10.1517/14656566.9.7.1249. Review. PubMed PMID: 18422481. 19: Kanofsky JA, Nitti VW. Tolterodine for treatment of overactive bladder. Urol Clin North Am. 2006 Nov;33(4):447-53, viii. Review. PubMed PMID: 17011380. 20: Abrams P. Evidence for the efficacy and safety of tolterodine in the treatment of overactive bladder. Expert Opin Pharmacother. 2001 Oct;2(10):1685-701. Review. PubMed PMID: 11825311.